Mean decrease in accuracy (MDA) of top 15 urine metabolites. by Liam E. Broughton-Neiswanger (8447220)

“…Urine metabolites with a mean decrease in accuracy ≥ 0.004 in at least one post-treatment time point (2–5) were considered for inclusion in the predictive model.…”

Infection with BVDV R₂, R₃ and R₅ leads to a decrease in dead cells. by Eliana F. Castro (581093)

Acute exercise decreased plasma insulin and glucose. by Mirian A. Kurauti (3146271)

Blocking C5L2 decreased MPO concentration in the supernatant of C5a-primed neutrophils. by Jian Hao (160736)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced degranulation. by Jian Hao (160736)

Increased endodiastolic volume and decreased ejection fraction in GJB4-deficient zebrafish. by Ryuji Okamoto (614374)

Activation, inactivation, and deactivation kinetics differ between Ca_V3.3 WT and variants as well as among the variants. by Yousra El Ghaleb (22075892)

Subjects:

Deletion of TXNIP decreases thioredoxin levels under hyperoxic conditions. by Mohammed A. Abdelsaid (287140)

“…<p>WT and TKO mice were subjected to 5 days hyperoxia (p7–12). …”

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…In the contralateral (unlesioned) hemisphere (CL), no difference was seen in the proportion of axons in the corpus callosum that were myelinated in Scribble cKO compared to wild-type animals (A–C). Fewer remyelinated axons were observed in corpus callosum in the lesion area in Scribble cKO mice (E) relative to controls (D) as quantified in F; 0.4–0.5 μm: WT = 80.0% ± 9.8%, cKO = 41.3% ± 8.9% myelinated; 0.5–0.6 μm: WT = 79.4% ± 6.3%, cKO = 41.5% ± 9.5% myelinated; 0.6–0.7 μm: WT = 91.6% ± 3.0%, cKO = 44.3% ± 8.7% myelinated; >0.7 μm: WT = 92.7% ± 1.9%, cKO = 47.9% ± 2.5% myelinated. …”

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

Tax expression is associated with decreased cellular motility. by Saumya Ramanayake (7879091)

Subjects:

Preserved NSS at 2 and at 24 hours following ischemia and decreased infarct volume in PAR1 KO mice 24 hours following ischemic stroke. by Efrat Shavit-Stein (3186678)

“…(C) Total infarct volume is significantly lower in PAR1 KO mice compared to control (t-test, WT = 6, PAR1 KO = 6). (D) Infarct volume decreases as a function of distance from the ischemic core (slices #5&6). …”

A homozygous point mutation in the <i>Mrps34</i> gene causes a decrease in the MRPS34 protein. by Tara R. Richman (713532)

“…The 5′- and 3′-untranslated regions are shown as grey boxes and the predicted mitochondrial targeting sequence is shown as a black box (predicted using MitoProtII, [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1005089#pgen.1005089.ref040" target="_blank">40</a>]). …”

Fluoxetine decreases TOPFlash firefly luciferase reporter activity. by Kentaro Miyamoto (123271)

<i>Dmd^mdx</i> rats are characterized by muscle weakness and by a decrease in a spontaneous activity. by Thibaut Larcher (331981)

“…<i>Dmd^mdx</i> rats showed fatigue with a decreased force grip across the five pulls, and significant values are obtained for the two last trials that were reduced to ∼70% when compared to Trial 1. …”

Total RNAP II levels decrease during WT HSV-1 KOS infection. by Mark Ou (474248)

Resveratrol decreased intracellular levels of R5P. by Mohd Askandar Iqbal (324124)

“…<p>R5P is a pentose phosphate pathway intermediate, an important marker for anabolism (nucleotide biosynthesis). …”

Decreased Tks5 expression results in neural crest-derived defects. by Danielle A. Murphy (212554)

“…<p>(A–B) Melanophores within the trunk region above the yolk sac extension in control MO-injected and Tks5 MO-injected embryos were qualitatively (A) and quantitatively (B) analyzed. n = 15 embryos and SEM is shown by bar. p values obtained from Student's t-test. ** denotes p<0.01. …”

Nicotine decreased Wnt5a expressions in SK-BR-3 cells. by Masanori A. Murayama (5774585)

Pretreatment of β-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. by Nevena Grdović (394542)